Expand ICCM Menu
ICCM MENU

ICCM Latest Press Releases

-- June 25, 2026 --

IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement PRNewswire 8:12 AM

-- June 23, 2026 --

IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer PRNewswire 8:10 AM

-- June 17, 2026 --

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor PRNewswire 1:15 PM
Biotech's New Frontier: Companies Breaking Through Medicine's Toughest Barriers Globe Newswire 10:37 AM
IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance PRNewswire 8:25 AM

-- June 2, 2026 --

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance PRNewswire 8:30 AM

-- May 19, 2026 --

IceCure's ProSense Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked PRNewswire 8:30 AM

-- May 13, 2026 --

IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement PRNewswire 4:30 PM

-- May 12, 2026 --

IceCure Reports First Quarter 2026 Financial Results: ProSense Sales Increase Substantially in the U.S. and North America PRNewswire 8:30 AM

-- May 5, 2026 --

IceCure Showcases ProSense Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market PRNewswire 8:30 AM

-- April 21, 2026 --

IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025 PRNewswire 8:30 AM

-- March 26, 2026 --

IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement PRNewswire 8:00 AM

-- March 25, 2026 --

IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates PRNewswire 8:30 AM

-- March 24, 2026 --

IceCure Appoints Meir Peleg as Chief Financial Officer PRNewswire 8:30 AM

-- March 17, 2026 --

IceCure Reports 2025 Full Year Financial & Operational Results PRNewswire 8:30 AM

-- March 11, 2026 --

U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense Cryoablation in the Local Treatment of Low-Risk Breast Cancer PRNewswire 8:30 AM

-- March 10, 2026 --

IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026 PRNewswire 8:30 AM

-- March 9, 2026 --

American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer PRNewswire 8:30 AM

-- March 2, 2026 --

IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas PRNewswire 8:30 AM

-- February 23, 2026 --

IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026 PRNewswire 8:30 AM

-- February 19, 2026 --

IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation PRNewswire 8:30 AM

-- February 11, 2026 --

IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense PRNewswire 8:30 AM

-- February 9, 2026 --

IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved PRNewswire 4:30 PM
Market Data Delayed 15 Minutes